Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CMPASS-EU
- Sponsors Bristol-Myers Squibb
- 03 Mar 2017 Status changed from active, no longer recruiting to completed.
- 02 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
- 02 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.